Immune predictors of hepatitis B surface antigen seroconversion in patients with hepatitis B reactivation
Authors:
- Mojahidul IslamMIMojahidul Islam
- Jayesh Kumar SevakJSJayesh Kumar Sevak
- Manoj Kumar SharmaMSManoj Kumar Sharma
- Ankur JindalAJAnkur Jindal
- Ashish Kumar VyasAVAshish Kumar Vyas
- Meenu BajpaiMBMeenu Bajpai
- Gayatri RamakrishnaGRGayatri Ramakrishna
- Shiv Kumar SarinSSShiv Kumar Sarin
- Nirupma TrehanpatiNTNirupma Trehanpati
- 21 November 2022
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (6) , 689-708
Abstract
Summary: Background: Hepatitis B surface antigen (HBsAg) seroconversion is sometimes observed in hepatitis B reactivation (rHBV), probably due to immune resetting and differentiation.Aims: To investigate sequential immune differentiation and abrogation of tolerance in patients with rHBV who achieved HBsAg seroconversion.Methods: We included 19 patients with chronic hepatitis B (CHBV; HBV DNA log103‐8), 67 with rHBV (raised ALT [>5XULN], HBV DNAlog104‐8) and 10 healthy controls. Immune differentiation, tolerance and functional status of CD4, CD8, T regulatory cells (Tregs), B cells and follicular T helper (Tfh) cells were assessed at baseline and 24 weeks.Results: At 24 weeks, 81% rHBV (n = 67) lost HBV DNA and HBeAg (41%), and 12 (19%) lost HBsAg and made anti‐HBs titers >10 IU/ml. rHBV patients had higher Th1/17, TEM, Tfh, Tfh1/17, plasma and ATM B cells, and lower Tregs, Th2, Th17 and TEMRA expression. rHBV showed lower PD1, TIM3, LAG3, SLAM and TOX compared to CHBV. There was a significant increase in CD8, CD8EM, Tfh, Tfh1/17 and plasma B cells in seroconverters than non‐seroconverters. At 24 weeks, we also observed increased plasma B cell frequency in seroconverters. While non‐seroconverters showed higher expression of PD1, TIM3, LAG3, SLAM and TOX on CD4/CD8 T cells, blockade of PD1, TIM3, LAG3 and CTLA4 significantly enhanced IFN‐γ, TNF‐α, IL‐4 and IL‐21 expression on CD4/CD8 and Tfh cells in non‐seroconverters.Conclusions: Non‐seroconverters have increased inhibitory markers on CD4/CD8 T cells. There is a critical play of CD8, Tfh and B cells and subsets in seroclearance, along with checkpoint molecules as a potential therapy for non‐seroconverters in HBV infection.Keywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology, India (BT/PR27792/BRB/10/1668/2018)
This publication has 59 references indexed in Scilit:
- Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis BBMC Gastroenterology, 2012
- IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosomeJournal of Clinical Investigation, 2012
- A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral InfectionPLOS Pathogens, 2011
- Viral persistence redirects CD4 T cell differentiation toward T follicular helper cellsJournal of Experimental Medicine, 2011
- Regulatory T cells and Foxp3Immunological Reviews, 2011
- Human Blood CXCR5+CD4+ T Cells Are Counterparts of T Follicular Cells and Contain Specific Subsets that Differentially Support Antibody SecretionImmunity, 2011
- An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective studyBMC Gastroenterology, 2007
- Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in VivoThe American Journal of Pathology, 2001
- Requirement of Mip-1α for an Inflammatory Response to Viral InfectionScience, 1995
- Macrophage Inflammatory Proteins: Biology and Role in Pulmonary InflammationExperimental Lung Research, 1994